Diabetes Drug Metformin Might Also Help Fight Cancer

SATURDAY, March 31 (HealthDay News) — A diabetes medication used by millions is now showing promise against a variety of different cancers.

Biomarker identified in relation to drug response in refractory urothelial cancer

( American Association for Cancer Research ) The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012.

Metformin appeared to slow prostate cancer growth

( American Association for Cancer Research ) The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Early clinical data show galeterone safe, effective against prostate cancer

( American Association for Cancer Research ) Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone, a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012.

Asuragen Awarded $6.8 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas (“CPRIT”). CPRIT was established to expedite innovation and commercialization in the area of cancer research and to enhance access to evidence-based …

State Institute Awards More Than $81 Million to Support Cancer Drug Discovery and Development in Texas

The Cancer Research and Prevention Institute of Texas today announced funding in excess of $81 million to support cancer research and commercialization projects in Texas. T